PeptiDream (4587) Q4 2024 earnings summary

Executive summary

• Achieved record revenue and profits in FY2024, with revenue reaching JPY 46.676 billion, a 163% year-over-year increase, and net income of JPY 15 billion, nearly 500% higher than FY2023, driven by expanded Novartis partnership and milestone payments.

• Number of clinical programs increased from 11 to 17, with continued pipeline expansion in radiopharmaceuticals and non-radiopharmaceuticals.

• Strategic shift to a "Platform + Portfolio" hybrid business model, aiming for sustained growth and further value creation.

• Major pipeline progress included advancing radiopharmaceutical programs into Phase 3 and new licensing deals, notably with Curium and Novartis.

Financial highlights

• FY2024 revenue reached JPY 46,676M, up 163% year-over-year, with core operating profit of JPY 21.2 billion (+296% YoY) and net income of JPY 15.01 billion (+495% YoY).

• Drug discovery and development revenue: JPY 31.3 billion; radiopharmaceutical revenue: JPY 15.36 billion.

• Earnings per share: JPY 115.85, a 495% increase from FY2023.

• Operating cash flow: JPY 23.8 billion; year-end cash: JPY 48.1 billion, supported by operating cash flow and sale of RayzeBio shares.

• No dividends declared; focus remains on reinvestment for growth.

Outlook and guidance

• FY2025 revenue forecast: JPY 49 billion, with core operating profit of JPY 21.7 billion and net income of JPY 15.1 billion.

• Guidance considered conservative, with upside potential from possible out-licensing deals, especially the myostatin program.

• Targeting continued pipeline expansion, new clinical candidates, and at least one NDA per year from 2027.

• Anticipates greater contribution from non-radiopharmaceuticals in 2025, with continued partnering and out-licensing.